These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25892204)

  • 1. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.
    Pinto A; Corazzelli G
    Br J Haematol; 2015 Nov; 171(4):665-8. PubMed ID: 25892204
    [No Abstract]   [Full Text] [Related]  

  • 2. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hodgkin lymphoma--ABVD regimen].
    Nagai H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():642-5. PubMed ID: 25831839
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
    Honda A; Nakamura F; Nannya Y; Shintani Y; Fukayama M; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jun; 93(6):1073-4. PubMed ID: 24173088
    [No Abstract]   [Full Text] [Related]  

  • 7. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.
    D'Arco AM; Califano C; Barone L; Belsito Petrizzi V; Iovino V; Langella M; Maglione V; Rivellini F; De Lorenzo S
    Br J Haematol; 2015 Nov; 171(4):662-5. PubMed ID: 25873239
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
    Ferrario A; Radaelli F; Goldaniga M; F FG; Olivero B; Rossi F; Baldini L
    Leuk Res; 2010 Oct; 34(10):e280-1. PubMed ID: 20605208
    [No Abstract]   [Full Text] [Related]  

  • 10. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired Glanzmann thrombasthenia associated with Hodgkin lymphoma: rapid reversal of functional platelet defect with ABVD (adriamycin/bleomycin/vinblastine/dacarbazine) chemotherapy.
    Raman V; Quillen K; Sloan JM
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e51-4. PubMed ID: 24342105
    [No Abstract]   [Full Text] [Related]  

  • 12. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes in studies of advanced Hodgkin's lymphoma.
    Johnson PW; Radford JA; Cullen MH; Sydes MR; Stenning SP; Hancock BW
    J Clin Oncol; 2006 Jul; 24(20):3309; author reply 3309-10. PubMed ID: 16829655
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is the ABVD an optimal regimen for Hodgkins disease?].
    Nakamura S
    Rinsho Ketsueki; 1998 Feb; 39(2):109-10. PubMed ID: 9545813
    [No Abstract]   [Full Text] [Related]  

  • 16. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP
    Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit.
    Phipps C; Lee YS; Hwang W
    Br J Haematol; 2012 Oct; 159(1):113-5. PubMed ID: 22823109
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
    Younes A; Fayad L; Romaguera J; Pro B; Goy A; Wang M
    Eur J Cancer; 2006 Nov; 42(17):2976-81. PubMed ID: 17008093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
    Constine LS
    J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.